Publications

  1. Stish BJ, Davis BJ, Mynderse LA, Deufel CL, Choo R. Brachytherapy in the Management of Prostate Cancer. Surg Oncol Clin N Am. 2017 Jul; 26: (3)491-513.
    View PubMed
  2. Westerman ME, Bhindi B, Choo R, Gettman MT, Karnes RJ, Klotz L, Boorjian SA. Media reporting of ProtecT: a disconnect in information dissemination? Prostate Cancer Prostatic Dis. 2017 May 02;
    View PubMed
  3. Wong WW, Anderson EM, Mohammadi H, Daniels TB, Schild SE, Keole SR, Choo CR, Tzou KS, Bryce AH, Ho TH, Quevedo FJ, Vora SA. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Apr 26;
    View PubMed
  4. Parker WP, Davis BJ, Park SS, Olivier KR, Choo R, Nathan MA, Lowe VJ, Welch TJ, Evans JD, Harmsen WS, Zaid HB, Sobol I, Moreira DM, Haloi R, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes RJ, Kwon ED. Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission TomographyComputed Tomography: A Nomogram for Predicting Extrapelvic Disease. Eur Urol. 2017 Mar; 71: (3)340-348.
    View PubMed
  5. Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ. Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. Int J Radiat Oncol Biol Phys. 2017 Mar 01; 97: (3)526-535.
    View PubMed
  6. Birckhead BJ, Fossum CC, Deufel CL, Furutani KM, Merrell KW, Schueler BA, Mynderse LA, Choo R, Davis BJ. Stranded seed displacement, migration, and loss after permanent prostate brachytherapy as estimated by Day 0 fluoroscopy and 4-month postimplant pelvic x-ray. Brachytherapy. 2016 Nov - Dec; 15: (6)714-721.
    View PubMed
  7. Jethwa KR, Furutani KM, Mynderse LA, Wilson TM, Choo R, King BF, Bergstralh E, Davis BJ. Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression. J Contemp Brachytherapy. 2016 Oct; 8 (5):371-378 Epub 2016 Nov 04
    View PubMed
  8. Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, Buskirk SJ. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. J Clin Oncol. 2016 Aug 1;
    View PubMed
  9. Wallis CJD, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, Shah PS, Danjoux C, Nam RK. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Jul; 70: (1)21-30.
    View PubMed
  10. Mayo CS, Pisansky TM, Petersen IA, Yan ES, Davis BJ, Stafford SL, Garces YI, Miller RC, Martenson JA, Mutter RW, Choo R, Hallemeier CL, Laack NN, Ma DJ, Olivier KR, Keole SR, Fatyga M, Foote RL, Haddock MG. Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review. Pract Radiat Oncol. 2016 Jul-Aug; 6: (4)e117-26.
    View PubMed
  11. Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, Danjoux C, Narod SA, Nam RK. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016 Mar 02; 352:i851.
    View PubMed
  12. Chu W, Loblaw DA, Chan K, Morton G, Choo R, Szumacher E, Danjoux C, Pignol JP, Cheung P. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer. Radiat Oncol. 2015; 10:95.
    View PubMed
  13. Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol. 2015; 5:90.
    View PubMed
  14. Ahmed KA, Davis BJ, Mynderse LA, Slezak JM, Bergstralh EJ, Wilson TM, Choo CR. Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol. 2014 Jul 29; 9:171.
    View PubMed
  15. Hallemeier CL, Davis BJ, Pisansky TM, Choo R. Late gastrointestinal morbidity in patients with stage I-II testicular seminoma treated with radiotherapy. Urol Oncol. 2014 May; 32(4):496-500. Epub 2013 Dec 12.
    View PubMed
  16. Paly JJ, Hallemeier CL, Biggs PJ, Niemierko A, Roeder F, Martinez-Monge R, Whitson J, Calvo FA, Fastner G, Sedlmayer F, Wong WW, Ellis RJ, Haddock MG, Choo R, Shipley WU, Zietman AL, Efstathiou JA. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2014 Mar 1; 88(3):618-23. Epub 2014 Jan 8
    View PubMed
  17. Hallemeier CL, Choo R, Davis BJ, Leibovich BC, Costello BA, Pisansky TM. Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma--the Mayo Clinic experience. Urol Oncol. 2014 Jan; 32(1):24.e1-6. Epub 2013 Mar 11
    View PubMed
  18. Hallemeier CL, Karnes RJ, Pisansky TM, Davis BJ, Gunderson LL, Leibovich BC, Haddock MG, Choo R. Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary bladder or ureter. Am J Clin Oncol. 2013 Dec; 36(6):596-600.
    View PubMed
  19. Hallemeier CL, Pisansky TM, Davis BJ, Choo R. Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience. Urol Oncol. 2013 Nov; 31(8):1832-8. Epub 2012 Apr 25.
    View PubMed
  20. Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2013 Apr 1; 85(5):1239-45. Epub 2012 Dec 19.
    View PubMed
  21. Khan L, Choo R, Breen D, Assaad D, Fialkov J, Antonyshyn O, McKenzie D, Woo T, Zhang L, Barnes E. Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer. Radiother Oncol. 2012 Aug; 104(2):263-6. Epub 2012 Jul 31.
    View PubMed
  22. Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Kiss A, Mamedov A, Deabreu A. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Jun 1; 83(2):617-23. Epub 2011 Nov 11.
    View PubMed
  23. Hallemeier CL, Choo R, Davis BJ, Pisansky TM, Gunderson LL, Leibovich BC, Haddock MG. Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Apr 1; 82(5):1938-43. Epub 2011 Apr 20.
    View PubMed
  24. Karnes R, Choo C, Call JA. Current Management Approach for Patients with PSA Relapse Following Radical Prostatectomy Interventional Oncology Society Journal.2012;2(1)37-47.
  25. Hallemeier CL, Pisansky TM, Davis B, Choo R. Long-term outcomes of radiotherapy for stage II testicular seminoma: The Mayo Clinic experience. J Clin Oncol. 2012 Feb 10; 30: (5_suppl)327.
    View PubMed
  26. Hallemeier CL, Pisansky TM, Davis B, Choo R. Long-term outcomes of radiotherapy for stage II testicular seminoma: The Mayo Clinic experience. J Clin Oncol. 2012 Feb 10; 30: (5_suppl)327.
    View PubMed
  27. Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Mamedov A, Deabreu A. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity. Int J Radiat Oncol Biol Phys. 2012 Feb 1; 82(2):898-905. Epub 2011 Jan 14.
    View PubMed
  28. Hertzig LL, Choo RC, Lightner DJ, Karnes RJ. Multimodal Treatment Approach to Advanced Female Urethral Squamous Cell Carcinoma Open Journal of Urology. 2012 29 Aug; 2(3):139-43.
  29. Choo CS, Mamedov A, Chung M, Choo R, Kiss A, Danjoux C. Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer. Nutr Res. 2011 Jan; 31(1):21-6.
    View PubMed
  30. Choo R, Quevedo F, Choo CS, Blute M. Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma? Can Urol Assoc J. 2010 Oct; 4: (5)E137-40.
    View PubMed
  31. Choo R, Long J, Gray R, Morton G, Gardner S, Danjoux C. Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. Support Care Cancer. 2010 Jun; 18(6):715-22. Epub 2009 Jun 09.
    View PubMed
  32. Choo R. Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges. Cancer Res Treat. 2010 Mar; 42: (1)1-11.
    View PubMed
  33. Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R. Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors. 2010; 2(4):e65. Epub 2010 Dec 31.
    View PubMed
  34. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Pearse M. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Int J Radiat Oncol Biol Phys. 2009 Nov 15; 75(4):983-9. Epub 2009 May 04.
    View PubMed
  35. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Pearse M. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins. Int J Radiat Oncol Biol Phys. 2009 Oct 1; 75(2):407-12. Epub 2009 Feb 11.
    View PubMed
  36. Pisansky TM, Gold DG, Furutani KM, Macdonald OK, McLaren RH, Mynderse LA, Wilson TM, Hebl JR, Choo R. High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer. Mayo Clin Proc. 2008 Dec; 83(12):1364-72.
    View PubMed
  37. Choo R, Pearse M, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):989-95. Epub 2008 Apr 23.
    View PubMed
  38. Pearse M, Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw A, Cheung P. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2008 Nov 1; 72(3):792-8. Epub 2008 Aug 15.
    View PubMed
  39. Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. J Urol. 2008 Oct; 180(4):1438-43; discussion 1443-4. Epub 2008 Aug 16.
    View PubMed
  40. Lim TS, Cheung PC, Loblaw DA, Morton G, Sixel KE, Pang G, Basran P, Zhang L, Tirona R, Szumacher E, Danjoux C, Choo R, Thomas G. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results. Int J Radiat Oncol Biol Phys. 2008 Sep 1; 72(1):85-92. Epub 2008 Mar 20.
    View PubMed
  41. Choo R, Pearce A, Danjoux C, Morton G, Deboer G, Szumacher E, Loblaw A, Cheung P. Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy. Eur Urol. 2007 Dec; 52(6):1645-50. Epub 2006 Nov 15.
    View PubMed
  42. Schwartz DJ, Sengupta S, Hillman DW, Sargent DJ, Cheville JC, Wilson TM, Mynderse LA, Choo R, Davis BJ. Prediction of radial distance of extraprostatic extension from pretherapy factors. Int J Radiat Oncol Biol Phys. 2007 Oct 1; 69(2):411-8.
    View PubMed
  43. Choo R, Kawakami J, Siemens R, Davis BJ, Brundage M, Pisansky TM. Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. BJU Int. 2006 Oct; 98(4):773-6.
    View PubMed
  44. Vieth R, Choo R, Deboer L, Danjoux C, Morton GC, Klotz L. Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summer. Am J Ther. 2006 Sep-Oct; 13(5):394-9.
    View PubMed
  45. Pearce A, Choo R, Danjoux C, Morton G, Loblaw DA, Szumacher E, Cheung P, Deboer G, Chander S. Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2006 May 1; 65(1):78-83. Epub 2006 Mar 24.
    View PubMed
  46. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005 Sep 1; 23(25):6132-8.
    View PubMed
  47. Choo R, Woo T, Assaad D, Antonyshyn O, Barnes EA, McKenzie D, Fialkov J, Breen D, Mamedov A. What is the microscopic tumor extent beyond clinically delineated gross tumor boundary in nonmelanoma skin cancers? Int J Radiat Oncol Biol Phys. 2005 Jul 15; 62(4):1096-9.
    View PubMed
  48. Chander S, Choo R, Danjoux C, Morton G, Pearse A, Deboer G, Szumacher E, Loblaw A, Cheung P, Woo T. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Int J Radiat Oncol Biol Phys. 2005 Jul 1; 62(3):719-24.
    View PubMed
  49. Cheung P, Sixel K, Morton G, Loblaw DA, Tirona R, Pang G, Choo R, Szumacher E, Deboer G, Pignol JP. Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer. Int J Radiat Oncol Biol Phys. 2005 Jun 1; 62(2):418-25.
    View PubMed
  50. Choo R, Thomas G, Woo T, Lee D, Kong B, Iscoe N, Danjoux C, Klotz L, Morton G, Chander S. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2005 Mar 1; 61(3):736-40.
    View PubMed
  51. Choo R, Morton G, Danjoux C, Hong E, Szumacher E, DeBoer G. Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate, carcinoma after surgery. Radiother Oncol. 2005 Feb; 74(2):163-7.
    View PubMed
  52. Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer. 2005; 51(1):32-6.
    View PubMed
  53. Choo R, Chander S, Danjoux C, Morton G, Pearse A, DeBoer G, Szumacher E, Loblaw A, Cheung P, Woo T. How are hemoglobin levels affected by androgen suppression in non-metastatic prostate cancer patients? Can J Urol.. 2005; 12: 2547-52.
    View PubMed
  54. Woo TC, Choo R, Chander S. An unusual case of concurrent breast and prostate cancer. Can J Urol. 2004 Oct; 11(5):2390-2.
    View PubMed
  55. Choo R, Klotz L, Deboer G, Danjoux C, Morton GC. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Int. 2004 Aug; 94(3):295-8.
    View PubMed
  56. Bagnell S, Choo R, Klotz LH, Chaterjee S. Practice patterns of Canadian urologists in the management of stage I testicular seminoma. Can J Urol. 2004 Apr; 11(2):2194-9.
    View PubMed
  57. Choo R, Do V, Sugar L, Klotz L, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer. Can J Urol. 2004 Feb; 11(1):2118-24.
    View PubMed
  58. Choo R, Sugar L, Hong E, Mackenzie K, DeBoer G, Danjoux C, Morton G, Klotz L. Is there a progression of histologic grade from radical prostatectomy to local recurrence in patients with clinically isolated local recurrence following surgery? Can J Urol. 2003 Oct; 10(5):1981-5.
    View PubMed
  59. Yap BK, Choo R, Deboer G, Klotz L, Danjoux C, Morton G. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone? BJU Int. 2003 May; 91(7):613-7.
    View PubMed
  60. Hruby G, Choo R, Jackson M, Warde P, Sandler H. Management preferences following radical inguinal orchidectomy for Stage I testicular seminoma in Australasia. Australas Radiol. 2002 Sep; 46(3):280-4.
    View PubMed
  61. Bunting PS, DeBoer G, Choo R, Danjoux C, Klotz L, Fleshner N. Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem. 2002 Sep; 35(6):471-5.
    View PubMed
  62. Do V, Choo R, Deboer G, Herschorn S, Danjoux C, Chen CH, Barak I. Urodynamic findings 3 months after radiotherapy in patients treated with conformal external beam radiotherapy for prostate carcinoma. BJU Int. 2002 Jul; 90(1):62-7.
    View PubMed
  63. Choo R, Hruby G, Hong J, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2002 Jun 1; 53(2):269-76.
    View PubMed
  64. Choo R, Do V, Herschorn S, DeBoer G, Danjoux C, Morton G, Cheng CH, Barak I, Preiner J. Urodynamic changes at 18 months post-therapy in patients treated with external beam radiotherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002 Jun 1; 53(2):290-6.
    View PubMed
  65. Klotz LH, Choo R, Morton G, Danjoux C. Expectant management with selective delayed intervention for favorable-risk prostate cancer. Can J Urol. 2002 Jun; 9 Suppl 1:2-7.
    View PubMed
  66. Do V, Choo R, De Boer G, Klotz L, Danjoux C, Morton G, Szumacher E, Fleshner N, Bunting P. The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int. 2002 May; 89(7):703-9.
    View PubMed
  67. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002 Apr; 167(4):1664-9.
    View PubMed
  68. Choo R, Sandler H, Warde P, Hruby G, DeBoer G. Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. Can J Urol. 2002 Apr; 9(2):1479-85.
    View PubMed
  69. Choo R, Hruby G, Hong J, Hong E, DeBoer G, Danjoux C, Morton G, Klotz L, Bhak E, Flavin A. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys. 2002 Mar 1; 52(3):674-80.
    View PubMed
  70. Lock M, Loblaw DA, Choo R, Imrie K. Disseminated intravascular coagulation and PC-SPES: a case report and literature review. Can J Urol. 2001 Aug; 8(4):1326-9.
    View PubMed
  71. Choo R, DeBoer G, Klotz L, Danjoux C, Morton GC, Rakovitch E, Fleshner N, Bunting P, Kapusta L, Hruby G. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys. 2001 Jul 1; 50(3):615-20.
    View PubMed
  72. Hruby G, Choo R, Klotz L, Danjoux C, Murphy J, Deboer G, Morton G, Rakovitch E, Szumacher E, Fleshner N. The role of serial transrectal ultrasonography in a 'watchful waiting' protocol for men with localized prostate cancer. BJU Int. 2001 May; 87(7):643-7.
    View PubMed
  73. Hruby G, Choo R, Lehman M, Herschorn S, Kapusta L. Female clear cell adenocarcinoma arising within a urethral diverticulum. Can J Urol. 2000 Dec; 7(6):1160-3.
    View PubMed
  74. Choo CR, Danjoux C, Morton G. Should pathological T3 and/or margin positive prostate cancer receive adjuvant therapy? A radiation oncologist's view. Can J Urol. 2000; 7:1043-50.
    View PubMed
  75. MacKenzie R, Balogh J, Choo R, Franssen E. Accelerated radiotherapy with delayed concomitant boost in locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1999 Oct 1; 45(3):589-95.
    View PubMed
  76. Nam RK, Fleshner N, Rakovitch E, Klotz L, Trachtenberg J, Choo R, Morton G, Danjoux C. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol. 1999 May; 161(5):1521-4.
    View PubMed
  77. Flavin A, Choo R, Franssen E, Danjoux C, Morton G. Pathological T3 and/or margin positive prostate adenocarcinoma with undetectable postoperative PSA - to irradiate or not?: analysis of freedom from PSA failure. Can J Urol. 1998 Jun; 5(2):544-550.
    View PubMed
  78. Choo R, Flavin A, Danjoux CE, Klotz LH. Can radiotherapy salvage isolated local recurrence following radical prostatectomy? Can J Urol. 1997 Sep; 4(3):395-399.
    View PubMed
  79. Choo R, Grimard L, Esche B, Crook J, Genest P, Odell P. Brachytherapy of neck metastases. J Otolaryngol. 1993 Feb; 22(1):54-7.
    View PubMed
  80. Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience. Cancer. 1991 Nov 15; 68(10):2120-4.
    View PubMed